Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis

doi:10.4330/wjc.v18.i3.112189

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (58)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-2)

Sum=66

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=2

Mar 26, 2026 (publication date) through Mar 24, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Cardiol. Mar 26, 2026; 18(3): 112189
Published online Mar 26, 2026. doi: 10.4330/wjc.v18.i3.112189

Table 1 Key characteristics of the included studies

Ref.	Study design	Population characteristics	Type of HF	Intervention	Control
Kosiborod et al[44], 2024	RCT (STEP-HFpEF DM)	O with HF and DM-II	HFpEF	Semaglutide (2.4 mg)	Placebo
Butler et al[45], 2023	RCT (STEP-HFpEF)	O with HF	HFpEF	Semaglutide (2.4 mg)	Placebo
Rehman et al[46], 2024	Retrospective	O with HF	HFpEF	Semaglutide (2.4 mg)	Placebo

O: Obesity; HF: Heart failure; RCT: Randomized control trial; DM-II: Type 2 diabetes; HFpEF: Heart failure with preserved ejection fraction.

Full Size Table

Table 2 Baseline characteristics, n (%)/median (25^th-75^th percentiles)

Ref.	mean ± SD	Total patients	Number of females	BMI		LVEF		Hypertension		CAD
Ref.	mean ± SD	Total patients	Number of females	Semaglutide	Placebo	Semaglutide	Placebo	Semaglutide	Placebo	Semaglutide	Placebo
Kosiborod et al[44]	69.0 ± 3.49	616	273	36.9 (33.6-41.5)	36.9 (33.5-41.1)	57.0 (50.0-61.0)	55.0 (50.0-60.0)	255 (82.3)	271 (88.6)	79 (25.5)	69 (22.5)
Butler et al[45]	68.5 ± 3.45	529	297	37.2 (33.9-41.1)	36.9 (33.3-41.6)	57.0 (50.0-60.0)	57.0 (50.0-60.0)	216 (82.1)	217 (81.6)	53 (20.2)	45 (16.9)
Rehman et al[46]	69.0 ± 3.47	318	172	37.2 (33.9-41.1)	36.9 (33.3-41.6)	57.0 (50.0-60.0)	57.0 (50.0-60.0)	82 (78.8)	163 (76.2)	23 (22.1)	47 (22.0)

BMI: Body mass index; LVEF: Left ventricular ejection fraction; CAD: Coronary artery disease.

Full Size Table

Citation: Mylavarapu M, Obi O, Abarca Y, Fatima H, Roshni P, Huda NU, Lysak Y, Gandapur A, Vazquez SC, Siddiqui MA, Mowo-Wale A. Semaglutide in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta-analysis. World J Cardiol 2026; 18(3): 112189
URL: https://www.wjgnet.com/1949-8462/full/v18/i3/112189.htm
DOI: https://dx.doi.org/10.4330/wjc.v18.i3.112189